A Series B financing round raised $63 million for Imara, which develops therapies for blood disorders. The funds will support development of Imara's lead candidate, IMR-687, being tested for sickle cell disease in a Phase IIa trial; a new therapy for beta-thalassemia; and expansion of its pipeline.
Alcon has paid $285 million for Tennessee-based fluid-based intraocular lens developer PowerVision and looks to make the latter's lens available to cataract patients worldwide. Alcon, which is expected to be spun out by its parent company, Novartis, will pay milestone payments of an undisclosed amount beginning in 2023 under the deal.
Biohaven Pharmaceuticals has acquired GW Pharmaceuticals' rare pediatric disease priority review voucher for $105 million. Biohaven plans to use the voucher to speed up its marketing application for Zydis, or rimegepant, a migraine drug.
Pairwise, an agriculture and food company, has licensed CRISPR genome-editing technologies from the Broad Institute and Massachusetts General Hospital, intending to use the technologies in research and development of new applications in food agriculture. "The high-fidelity and enhanced CRISPR enzymes with improved target recognition capabilities that we have developed for medical uses also have the potential to increase gene editing efficiencies and could ultimately increase the pace of innovation in agriculture," says Pairwise co-founder J. Keith Joung.
GranBio, a Brazilian industrial biotechnology firm, has acquired biorefineries in the US, including American Process, AVAPCO and API Intellectual Properties. The deal covers acquisition of Alpena Biorefinery; the Thomaston Biorefinery plus its research and development center; and intellectual property related to biofuels, biorefinery, biochemicals and nanocellulose, including 200 pending and current patents.
A round of Series B financing has brought in $35 million for Israel-based biomedical technology company Theranica. The proceeds will be used for mass production of the company's Nerivio Migra remote neuromodulation device for treating migraine, which is under FDA review.
Think Surgical has reached a global joint marketing deal with United Orthopedic to combine the latter's U2 knee system with Think's Active robotic system. Under the agreement, United will exclusively distribute Think's products in Taiwan, which will be considered a center of excellence for the combined systems.
Australian diagnostic maker SpeeDx has reached a distribution partnership with Al Zahrawi Medical Supplies in hopes of expanding its presence in the Middle East. Under the deal, the SpeeDx ResistancePlus and PlexPCR tests will be distributed in the UAE, Bahrain, Qatar, Saudi Arabia and Oman.
Study data show use of Edwards Lifesciences' Sapien 3 transcatheter aortic valve replacement system and Medtronic's Evolut R, Evolut Pro and CoreValve devices in low-risk patients led to lower rates of death and stroke, and shorter hospital and recovery times, compared with traditional valves. The data will be submitted to the FDA to seek low-risk indications for these devices, which are already approved for high- and intermediate-risk patients.